SEC Form 4 · accession 0001225208-17-007643
BOSTON SCIENTIFIC CORP · BSX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stephen P Macmillan
Director
Period of report
Apr 3, 2017
Accepted (ET)
Apr 5, 2017 · 4:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000885725
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Deferred Stock UnitsF2,F1,F3 | — | Apr 3, 2017 | A | 677 | A | — | — | Common Stock | 677 | 16,894 | D |
| Stock Option (Right to Buy)F4 | $24.92 | Apr 3, 2017 | A | 827 | A | — | Apr 3, 2027 | Common Stock | 827 | 827 | D |
Explanation of responses
- F1Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
- F2Reflects a value of $16,875 divided by the closing price of common stock on the date of grant.
- F3Deferred stock units were granted in lieu of 75% of the quarterly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan.
- F4Reporting person received 25% of the cash compensation for the first quarter of 2017 in the form of an option to purchase a specified number of shares of common stock vesting in full upon the 2017 annual meeting of stockholders.